5F61 | date | ![]() |
|||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
authors | |||||||||||||||
compound | source | ||||||||||||||
symmetry |
| ||||||||||||||
crystal cell |
| ||||||||||||||
method | X-Ray Diffraction | resolution | |||||||||||||
ligand | 5W0, EDO | enzyme |
| ||||||||||||
Primary reference | Potent dual BET bromodomain-kinase inhibitors as value added multi-targeted chemical probes and cancer therapeutics., Ember SW, Lambert QT, Berndt N, Gunawan S, Ayaz M, Tauro M, Zhu JY, Cranfill PJ, Greninger P, Lynch CC, Benes CH, Lawrence HR, Reuther GW, Lawrence NJ, Schonbrunn E, Mol Cancer Ther. 2017 Mar 23. pii: molcanther.0568.2016. doi:, 10.1158/1535-7163.MCT-16-0568-T. PMID:28336808 |
Data retrieval |
![]() |
View 5F61 in 3D |
![]() |
Structure-derived information |
Sequence-derived information |
OCA© by Jaime Prilusky, 1996-2014,2022,2024 Bioinformatics Unit Weizmann Institute of Science |